JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21

Futu NewsFeb 19 23:31

Truist Financial Initiates Larimar Therapeutics(LRMR.US) With Buy Rating, Announces Target Price $18

Futu NewsJan 29 21:31

Truist Initiates Larimar Therapeutics at Buy With $18 Price Target

MT NewswiresJan 29 19:22

Larimar Therapeutics Analyst Ratings

BenzingaJan 24 20:04

H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15

Futu NewsJan 24 19:31

JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21

Futu NewsJan 24 15:32

JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21

Futu NewsJan 24 07:31

JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $21

Futu NewsDec 21, 2024 02:41

Baird Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $13

Futu NewsDec 18, 2024 00:31

Oppenheimer Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $26

Futu NewsDec 17, 2024 21:31

A Quick Look at Today's Ratings for Larimar Therapeutics(LRMR.US), With a Forecast Between $14 to $36

Futu NewsDec 17, 2024 21:00

Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR) and Ascendis Pharma (ASND)

TipRanksDec 17, 2024 02:28

Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow JonesDec 17, 2024 01:12

Promising Developments and Strategic Regulatory Support Justify Buy Rating for Larimar Therapeutics

TipRanksDec 17, 2024 01:08

Larimar Therapeutics Analyst Ratings

BenzingaDec 17, 2024 01:02

LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $36

Futu NewsDec 7, 2024 00:31

Positive Outlook on Larimar Therapeutics' Nomlabofusp for Friedreich's Ataxia: Analyst Recommends Buy Rating

TipRanksDec 6, 2024 23:47

JMP Securities Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Cuts Target Price to $21

Futu NewsDec 6, 2024 01:35

Analysts Offer Insights on Healthcare Companies: Phreesia (PHR), Larimar Therapeutics (LRMR) and Merus (MRUS)

TipRanksDec 6, 2024 01:28

H.C. Wainwright Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $15

Futu NewsNov 19, 2024 16:42